Laboratory Corporation of America Holdings

Tweet this page
<
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 03 Aug 2017
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

450,000€

Financial year: Jan 2016 - Dec 2016

Lobbyists (Full time equivalent)

1.5 Fte (4)

Lobbyists with EP accreditation

1

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    Laboratory Corporation of America Holdings   (LabCorp)

    EU Transparency Register

    878238423039-24 First registered on 17 Aug 2016

    Goals / Remit

    Laboratory Corporation of America® Holdings together with its subsidiaries is a world leading life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. The Company’s mission is to improve health and improve lives by delivering world-class diagnostics solutions, bringing innovative medicines to patients faster and using technology to provide better care.

    Main EU files targeted

    • Directive 2001/20/EC relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use.

    • Regulation 536/2014 on clinical trials on medicinal products for human use

    • Directive 98/79/EC on in vitro diagnostic medical device

    • Commission Directive (EU) 2015/566, as regards the procedures for verifying the equivalent standards of quality and safety of imported tissues and cells

    • Directive 2010/63 on protection of animals used for scientific purposes

    • Regulation (EC) No 178/2002 laying down the general principles and requirements of food law

    • Directive 95/46/EC on the protection of individuals with regard to the processing of personal data and on the free movement of such data

    • U.S. Safe Harbor Decision 2000/520 (invalidated by ECJ on 6 October 2015)

    Address

    Head Office
    531 South Spring Street
    Burlington 27215
    UNITED STATES
  • People

    Total lobbyists declared

    4

    Employment timeLobbyists
    75%1
    25%3

    Lobbyists (Full time equivalent)

    1.5

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    1 accreditations were / are live (in bold) for the selected state of 03 Aug 2017

    Name Start date End Date
    Sabine Schneider Nash 06 Mar 2024 05 Mar 2025
    Sabine Schneider Nash 05 Nov 2019 31 Oct 2020
    Sabine Schneider Nash 28 Oct 2016 28 Oct 2017

    Complementary Information

    None declared

    Person in charge of EU relations

    Ms Sabine Schneider Nash (VP Government Relations and Communications Europe/APAC)

    Person with legal responsibility

    Ms Sandra Van der Vaart (VP Legal)

  • Categories

    Category

    II - In-house lobbyists and trade/business/professional associations

    Subcategory

    Companies & groups

  • Networking

    Affiliation

    - European Federation of the Pharmaceutical Industry and Associations (EFPIA), Partner in Research
    - Association of the British Pharmaceutical Industry (ABPI), Research Affiliate
    - European Animal Research Association (EARA)
    - Association of Clinical Research Associations (ACRO)
    - Antimicrobial Resistance Alliance

    Member organisations

    None declared

  • Financial Data

    Closed financial year

    Jan 2016 - Dec 2016

    Lobbying costs for closed financial year

    450,000€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    Access Benefit Sharing (ABS) working group

    ACC

    None

    Groups (European Parliament)

    None

    Communication activities

    LabCorp currently focuses on monitoring legislation, policies and directives and working through Associations such as EFPIA and ACRO to give guidance on areas impacted.

    Other activities

    • LabCorp started in February 2016 to implement a Public Affairs programme in Europe.
    • LabCorp is a Partner in Research at EFPIA and has access to the EU funded Innovative Medicine Initiative (IMI).

  • Meetings

    Meetings

    None declared

Download this datacard